Stock 9966 ALPHAMAB ONCOLOGY
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Alphamab Oncology

Equities

9966

KYG0330A1013

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:06 2024-04-30 am EDT 		5-day change 1st Jan Change
4.75 HKD +0.21% Intraday chart for Alphamab Oncology +13.91% -28.46%
Apr. 10 Alphamab Oncology Presents Phase-I Clinical Trial Results at 2024 AACR Annual Meeting MT
Apr. 10 Alphamab Oncology Presented the Dose-Escalation Results from Jskn003 in Patients with Advanced/Metastatic Solid Tumors At Aacr CI

Evolution of the average Target Price on Alphamab Oncology

Price target over the last 5 years

History of analyst recommendation changes

be50d0557891e9d6d6f.0m5IYXWZK2ZN_HaF3-p0uCmEa-ohU2EW1EcVbivEdAY.hQoaFEPBRCMGsjvQm4Ak4WroLaZiIwoj4hVZVgaILT-AFiwURe1NIWCPAQ~22568ce49485dc46499488901378a9f0

Analyst Recommendations on Alphamab Oncology

UBS Adjusts Alphamab Oncology's Price Target to HK$12.94 From HK$13.22, Keeps at Buy MT
Nomura Adjusts Alphamab Oncology's Price Target to HK$13.22 From HK$13.89, Keeps at Buy MT
ALPHAMAB ONCOLOGY : Nomura Adjusts Alphamab Oncology's Price Target to HK$28.8 From HK$25.1, Keeps at Buy MT
ALPHAMAB ONCOLOGY : Nomura Adjusts Alphamab Oncology's Price Target to HK$25.1 From HK$17.2, Keeps at Buy MT
ALPHAMAB ONCOLOGY : Nomura Starts Alphamab Oncology at Buy With HK$17.2 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
4.396 CNY
Average target price
4.211 CNY
Spread / Average Target
-4.20%
High Price Target
4.879 CNY
Spread / Highest target
+10.99%
Low Price Target
3.326 CNY
Spread / Lowest Target
-24.34%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Alphamab Oncology

UBS
Nomura

Ratings for Alphamab Oncology

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. 9966 Stock
  4. Consensus Alphamab Oncology